Infinity Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Infinity Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count).
Infinity Pharmaceuticals: 17 sponsored US clinical trials, none currently recruiting.
Infinity Pharmaceuticals sponsors 17 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 13 completed. 0 of these trials are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cancer of the Prostate, with 1 trials.
Top-decile sponsor footprint
Infinity Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
13 of 17 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (76.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
17 total, page 1 of 1
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
NCT03980041
IPI-926 Extension Protocol for Continuation of Treatment With IPI-926
NCT01609179
A Phase 2 Study With IPI-926 in Patients With Myelofibrosis
NCT01371617
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
NCT01427946
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
NCT01362400
A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma
NCT01310816
Dose Escalation of IPI-493 in Hematologic Malignancies
NCT01193491
A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer
NCT01130142
Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer
NCT00817362
A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies
NCT00761696
A Phase 1 Dose Escalation Study of IPI-493
NCT00724425
A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma
NCT00627419
Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors
NCT00606814
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer
NCT00564928
Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)
NCT00431015
Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)
NCT00276302
Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma
NCT00113204
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 7 |
Therapeutic Areas
How the Infinity Pharmaceuticals early-phase archive is shaped
17 indexed studies, none listed as recruiting (0% open); 13 completed (76%).
Phase mix: 0 late (III/IV) vs 16 early (I/II) (early-phase heavy).
Top condition: Cancer of the Prostate (1 trial), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Infinity Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 17 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Infinity Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 17 archived trials
- Achieve Life Sciences · 17 trials · 0% recruiting
- BioDelivery Sciences International · 17 trials · 6% recruiting
- Chugai Pharmaceutical · 17 trials · 24% recruiting
- ConvaTec · 17 trials · 18% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Infinity Pharmaceuticals page
17 registered trials is a research-attention snapshot, not an endorsement of Infinity Pharmaceuticals or any single study.
- None of Infinity Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Cancer of the Prostate is the condition Infinity Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cancer of the Prostate trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Infinity Pharmaceuticals pipeline card: 17 registered trials from official public datasets.Report a data error.